Science and Technology

Archive | news

May 16, 2017

X-Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration

[Download PDF] X-Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration – Agreement will enable discovery of small-molecule leads against validated targets for severe, genetic diseases – X-Chem to receive upfront payment and potential research, development and regulatory milestones and licensing fees, plus additional royalties on future sales WALTHAM, Mass. – May 15, 2017 – […]

Continue Reading
April 26, 2017

X-Chem Announces Publication in Nature

WALTHAM, Mass. –April 26, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-encoded library platform (DEXTM) to the discovery of the next generation of small molecule therapeutics, announced today a publication in Nature. The article, co-authored by scientists from AstraZeneca Inc. and Heptares, Inc., describes the crystal structure of protease-activated […]

Continue Reading
March 21, 2017

X-Chem and Ono Enter into Multi-Target Drug Discovery Collaboration

WALTHAM, Mass. – March 21, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced a partnership with Ono Pharmaceutical Co., Ltd. (Ono). Under the terms of the agreement X-Chem will apply its proprietary DEXTM libraries, which contain over […]

Continue Reading
March 20, 2017

X-Chem Announces Strategic Collaboration with Astellas Pharma Across Multiple Therapeutic Areas

WALTHAM, Mass. – March 20 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc. (Astellas). The collaboration will enable the discovery of novel lead compounds for complex […]

Continue Reading
February 15, 2017

X-Chem Expands Collaboration with Janssen in Inflammatory Diseases

WALTHAM, Mass. – February 15, 2017 – X-Chem, Inc. (X-Chem) announced today that it has expanded its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties’ existing discovery and license partnership, […]

Continue Reading
December 20, 2016

X-Chem Announces Multi-Target Drug Discovery Collaboration with Taiho Pharmaceutical using DEX™ Technology

WALTHAM, Mass. – December 20, 2016 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced that it entered into a multi-target drug discovery collaboration with Taiho Pharmaceutical Co. Ltd. This collaboration will grant Taiho access to X-Chem’s DEX™ […]

Continue Reading
July 26, 2016

X-Chem and AbbVie Enter into Multi-Target Drug Discovery Partnership

WALTHAM, Mass. – July 26, 2016 – X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, today announced a multi-target drug discovery agreement with AbbVie. The collaboration is focused on the discovery and development of novel treatments for diseases in oncology and immunology. […]

Continue Reading
July 12, 2016

X-Chem and Bayer Expand Drug Discovery Collaboration to Discover Novel Medicines

WALTHAM, Mass. – July 12, 2016 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, and Bayer have entered into an expanded global drug discovery collaboration across multiple therapeutic areas and target classes. The new agreement extends Bayer’s access to […]

Continue Reading
April 27, 2016

X-Chem Announces Achievement of Milestone in Alexion Collaboration

WALTHAM, Mass. – April 27 2016 – X-Chem, Inc. (X-Chem), a privately held biotechnology company utilizing its industry-leading DNA-Encoded X-Chem (DEX™) drug discovery platform for the identification of first-in-class small molecule therapeutics, today announced that it has achieved a milestone in its drug discovery collaboration with Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), triggering a payment to […]

Continue Reading
March 30, 2016

X-Chem Announces License with Janssen for Protein:Protein Inhibitor Program in Inflammatory Disease

WALTHAM, Mass. – March 30, 2016 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-Encoded X-Chem (DEX™) drug discovery platform to generate novel therapeutics, today announced that a licensing option with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has been exercised for a protein inhibitor […]

Continue Reading